Androgen excess (hyperandrogenism) is a common endocrine disorder affecting women of reproductive age. The potential causes of androgen excess in women include polycystic ovary syndrome, congenital adrenal hyperplasia (CAH), adrenal tumors, and racial disparity among many others. During pregnancy, luteoma, placental aromatase deficiency, and fetal CAH are additional causes of gestational hyperandrogenism. The present report reviews the various phenotypes of hyperandrogenism during pregnancy and its origin, pathophysiology, and the effect of hyperandrogenism on the fetal developmental trajectory and offspring consequences. (Endocrinology
D
evelopmental programming is a complex process whereby perturbed intrauterine environment during a critical period of development leads to alterations in the developmental trajectory of the growing fetus (1) . These changes can affect gene expression and the structure and function of the developing organs, eventually leading to adaptive and beneficial postnatal consequences or maladaptive postnatal consequences. Examples of insults (in utero, early postnatal life) resulting in developmental programming include placental/fetal hypoxic insults (2) , nutritional deprivation (3), overnutrition (4) , stress (5) , maternal nicotine (6) , and exposure to environmental endocrine-disrupting chemicals (7) . The fetomaternal hormonal milieu plays an important role during the critical development periods of organ differentiation in the fetus (8) . Therefore, maternal hormone disturbances can affect fetal growth either directly or indirectly by affecting placental growth and function. Alterations in fetal developmental trajectory could also be facilitated through changes in fetal metabolism or changes in the production of hormones or growth factors by fetoplacental tissues. Perturbations in maternal-fetal insulin, androgens, glucocorticoids, and thyroid hormone are some known causes that lead to adaptive or maladaptive developmental programming (8) .
An altered sex steroid milieu is an example of in utero disruption that adversely programs the developing fetus. Some examples of a perturbed sex steroid hormone milieu in utero include disease states such as polycystic ovary syndrome (PCOS) and congenital adrenal hyperplasia (CAH), the maternal use of anabolic steroids, continued maternal contraceptive steroid use, and exposure to steroidogenic environmental endocrine-disrupting chemicals such as bisphenol A (BPA), trenbolone, diethylstilbestrol, and polychlorinated biphenyls (9) . The present review addresses our current understanding of the normal and abnormal gestational androgen milieus and its effect on offspring health.
The androgen profile in women includes dehydroepiandrosterone sulfate (DHEAS), androstenedione (A4), testosterone, and dihydrotestosterone (12) , which are synthesized in the ovaries, adrenal glands, and fat. Androgens, through the process of aromatization, lead to estrogen production in both males and females (13) .
During pregnancy, the fetal gonads and placenta influence the fetal androgen milieu. Substantial changes in the circulating concentrations of androgens (testosterone, A4, and DHEAS) and their binding proteins occur during the normal progression of pregnancy (14) . Maternal serum testosterone concentrations start to increase in the first trimester and demonstrate increasing levels throughout pregnancy, irrespective of fetal sex, peaking at the end of gestation and declining postpartum (15, 16) . In mothers carrying female fetuses, the serum testosterone concentration ranges from 0.5 to 2.06 ng/mL through gestation. In those carrying male fetuses, the maternal serum testosterone concentration ranges from 0.52 to 2.12 ng/mL through gestation (15) . Maternal serum A4 concentrations increase in the later part of pregnancy, peaking in the third trimester (15, 16) . DHEAS has been shown to decline from the first trimester until birth (16, 17) ; however, a more recent meta-analysis demonstrated a fluctuating pattern of maternal DHEAS serum concentrations throughout gestation (15) .
Additionally, a decrease in the metabolic clearance rate of testosterone is also evident during pregnancy compared with nonpregnant women (18) . The increase in testosterone levels throughout gestation, in addition to serving as a substrate for estrogen production, is likely important for the establishment and maintenance of pregnancy and initiation of parturition (19) . Androgens work on components critical for term pregnancy. Dihydrotestosterone is thought to play a role in promoting the cervical ripening that initiates labor in animal models (20) , and DHEAS has been shown to promote the same in human studies (19) . Some evidence from animal and human studies has shown that androgens play a role in relaxation of the myometrium (21) .
Despite increases in both total and free testosterone during normal pregnancy, women and their female infants appear unaffected. This might be because the elevated testosterone levels activate protective measures to reduce excess androgen exposure in both the mother and the fetus. First, an increase in sex hormone-binding globulin is able to bind testosterone and dihydrotestosterone (22) , reducing free androgen exposure. Second, placental aromatase cytochrome P450 plays a critical role in counteracting the effects of excess testosterone and DHEAS in maternal and fetal adrenal glands. Placental aromatase converts these androgens into estradiol, which is subsequently converted to estriol by the fetal liver and excreted in the maternal urine (22) . However, if an abnormality is present in adrenal or ovarian function, leading to excess androgen production by the mother or fetus that exceeds the capacity of these protective measures, the functional capacity of aromatase would be exceeded, leading to a hyperandrogenic state. In support of this, aromatase expression was reduced and the androgen levels were increased during pregnancy in women with PCOS (16, 23) .
Several epidemiological studies have demonstrated racial disparities in the androgen levels in pregnant women (24, 25) . Clinically important differences in the maternal hormonal milieu have been reported in blacks, Hispanics, and whites. Evidence has suggested that maternal androgen (A4, testosterone) levels are higher in Hispanic and African-American women compared with white women, with the highest levels found in AfricanAmerican women in the first trimester (11 weeks of gestation) (24) . Other studies have found maternal testosterone levels to be 48% greater in African-American women relative to white women during the early weeks of gestation (before 12 weeks) (25) . Furthermore, higher testosterone levels and molar ratios of testosterone to sex hormone-binding globulin have also been demonstrated in the cord blood of African-American offspring compared with whites (26) . Although the etiology of differences in androgen levels among different ethnic groups is not completely understood, it has been postulated that several factors could play a role, including genetics, diet, and environmental factors (27, 28) . Further research of the disparity of race and ethnicity on gestational androgens and its etiology is necessary to expand on these hypotheses.
Phenotypes of Maternal and Fetal Hyperandrogenism
The clinical maternal presentation of hyperandrogenism during pregnancy includes hirsutism in androgendependent areas (upper lip, chin, abdomen, groin, thigh, and chest), facial and body acne, hair loss, and hair thinning in the temporoparietal area (22) . Other clinical presentations include the onset of masculinizing symptoms such as clitoromegaly and a deepening voice (22) . Excess androgens during pregnancy can stem from various sources from the mother and developing fetus. Maternal hyperandrogenic states stem from ovarian tumor/luteoma (29) , hyperreactio luteinalis (30), PCOS (16) , and adrenal tumors (31) . Fetal-derived sources for elevated androgens include CAH (32, 33) , placental aromatase deficiency (34) , and exposure to maternal nicotine (35) . Evidence exists of maternal elevation in androgen levels with preeclampsia thought to be due to placental aromatase deficiency (36, 37) and AfricanAmerican ancestry (24) . The various phenotypes of gestational hyperandrogenism (Fig. 1) are discussed in the subsequent sections in greater detail.
Polycystic ovary syndrome
PCOS is the most common endocrine disorder in women of reproductive age, primarily characterized by hyperandrogenism and reproductive abnormalities (38) . It is also associated with a number of metabolic perturbations, including obesity, insulin resistance, and an increased risk of type 2 diabetes, dyslipidemia, and cardiovascular disease (39) . The etiology of PCOS remains unknown owing to its complex pathophysiology; however, it has been shown that women with a classic 21-hydroxylase deficiency (another phenotype of hyperandrogenism discussed later in the present report) exhibit features that closely mimic those found in PCOS [e.g., anovulation, ovarian hyperandrogenism, luteinizing hormone (LH) hypersecretion], suggesting that androgen excess early in life might provide a possible mechanism for the development of PCOS (32) . Pregnant women with PCOS are reported to have higher levels of DHEAS, A4, and testosterone compared with normal pregnant women (16, 40) .
Luteoma and hyperreactio luteinalis (theca-lutein cysts of ovaries)
Two of the most common causes of gestational hyperandrogenism are luteomas and theca-lutein cysts of the ovary (41) . A luteoma is a benign tumor of the ovary during pregnancy, which often goes unnoticed. Most cases have reported luteomas as small and/or nonvirilizing cysts that regress in the postpartum period (41) . Excess androgen production is evident in one-third of all luteomas, which corresponds to virilization in 25% to 35% of mothers. The female fetus will be afflicted with virilization in two thirds of virilized mothers (22) . Longterm implication of androgen exposure secondary to the luteomas in pregnancy on maternal and fetal health is unknown, and further research is required.
Placental aromatase deficiency
Aromatase is a key cytochrome P450 enzyme in the synthesis of estrogens from androgens. As stated previously, aromatase expression in the placenta protects the mother from the potentially androgenizing effects of fetal adrenal androgens during pregnancy (42) . Aromatase deficiency is an autosomal recessive disorder due to mutations in the CYP19A1 gene (43) . The clinical features of aromatase deficiency include maternal virilization during pregnancy, fetal virilization of external genitalia, and symptoms of ovarian cysts in childhood (44) . The phenotype of aromatase deficiency is similar to that of androgen excess. Disease processes such as preeclampsia and placental ischemia have recently been shown to lead to diminished placental aromatase expression and functionality (37) .
Congenital adrenal hyperplasia
CAH is an inherited autosomal recessive disease that occurs from an enzyme deficiency within the adrenal gland responsible for the production of cortisol and aldosterone (45). 21-Hydroxylase-enzyme deficiency is the most common cause of CAH. 21-Hydroxylase-enzyme deficiency results in overproduction of adrenal androgens at around 7 weeks of gestation (46) and can lead to a simple virilizing CAH or a more severe, salt-wasting CAH at birth (45, 47) . Clinically, CAH can result in marked virilization of the external genitalia of affected female subjects (33) . Fertility has been reported to be low in women with CAH and thought to result from suboptimal disease control. Live birth outcomes have ranged from 0% to 10% for women with salt-wasting CAH to 33% to 50% for women with the simple virilizing forms, and 63% to 90% for those with nonclassic CAH, according to 1 study (48) . These women have an increased incidence of gestational diabetes thought to be secondary to glucocorticoid use (49). CAH is also a known example of fetal origin of hyperandrogenism in utero. Since the use of dexamethasone 30 years ago during pregnancy in at-risk female fetuses with CAH, the data on the direct effect of excess adrenal androgen on fetal outcome is not clear. More studies assessing the pregnancy outcomes of women with CAH or those carrying a fetus with CAH in their womb are required to assess the direct effects of adrenal hyperandrogenism in utero.
Adrenal tumors
Carcinoma or adenoma of the maternal adrenal gland can lead to hyperandrogenism during gestation (31). Although extremely rare, it can result in increased maternal and fetal morbidity and mortality. Some of the presenting features of adrenal carcinoma include virilization, hypertension, diabetes mellitus, muscle wasting, and depression in the mother (29) . Additionally, excess maternal cortisol and androgen secretion has been shown to cause partial virilization and ambiguous genitalia in female infants (50) .
Exposure via environmental steroidomimetics
Increasing evidence has shown that environmental factors can have adverse effects during development. These chemicals in the environment, food, and consumer products [termed endocrine-disrupting chemicals (EDCs)] can interfere with hormone biosynthesis and metabolism (7) through steroid receptor signaling or modulation of steroid biosynthesis. Examples of EDCs that alter the androgenic milieu or increase androgen levels during pregnancy include 17b-trenbolone (51), BPA (52) , and phthalates (53) . BPA, a component of plastic, regulates 17a-hydroxylase enzyme activity (54) and could lead to overproduction of androgen by the ovarian theca-interstitial cells. Additionally, it has been shown that women with PCOS have elevated levels of BPA (55) . The demonstrated increase in testosterone in PCOS women is consistent with decreased clearance of BPA (56) . Phthalates, also used in the plastic industry (53), act as steroidomimetics to impair steroidogenesis in ovarian follicular cells (57) . Gestational exposure to dibutyl phthalate and di(2-ethylhexyl)phthalate has been shown to result in polycystic ovaries and a hormonal profile similar to that of PCOS (58) .
17b-Trenbolone is an androgenic EDC frequently used in the cattle industry (59) to promote growth (60) . Although to the best of our knowledge trenbolone levels have not been studied in human pregnancy, pregnant rats treated with trenbolone acetate manifest increases in neonatal anogenital distance and delayed onset of puberty (51) . Additionally, rainbow trout exposed to trenbolone demonstrated developmental delays (61) .
Further studies are necessary to investigate the additional adverse maternal and fetal programming effects of androgenic EDCs and their cause-and-effect relationships.
Preeclampsia
Preeclampsia is a pregnancy state of hypertension, proteinuria, and edema that develops after the 20th week of gestation affecting 3% to 5% of all pregnancies (62) . The etiology of the condition is not completely understood; however, the pathological mechanisms include defective deep placentation and impaired remodeling of the maternal uterine spiral arteries. Preeclampsia has been associated with elevated maternal levels of androgens, in particular, testosterone and A4 (63) . Recently, it has been shown that the placental aromatase enzyme that is responsible for the conversion of androgens to estrogen is deficient in placental ischemia and preeclamptic pregnancy (37) , which could explain the noted elevation of maternal androgens during preeclampsia. Elevated androgens have also been postulated to play an important role in the etiology of preeclampsia, although the mechanism is not clear (64) .
Recent studies in rats have suggested a role for androgens in inducing key features of preeclampsia, including elevated mean arterial pressure, proteinuria, and systemic endothelial dysfunction (65) . Although a positive correlation seems to exist between preeclamptic pregnancy and androgen levels, the published data remain controversial. Additional studies are necessary to further delineate the relationship between androgens and preeclampsia.
Obesity
Maternal obesity is a major risk factor for several maternal metabolic complications (66) . Obesity exacerbates hormonal and clinical features of PCOS (67) and increases the risk of comorbidities associated with PCOS, such as impaired glucose tolerance, type 2 diabetes mellitus, hyperlipidemia, and arterial hypertension (68) . Obesity exacerbates hyperandrogenism in women with PCOS, which results in increased total testosterone, free androgen index, and decreased sex hormone-binding globulin (69) . Obese women with PCOS exhibit a greater degree of insulin resistance and hyperinsulinemia, further contributing to elevated androgen levels (69) . The exact cause-and-effect relationship between obesity and hyperandrogenism in pregnancy remains to be determined. Obesity and accompanying hyperglycemia promote chronic low-grade inflammation and increased cytokine production in adipose tissue (70) , which, in turn, has the potential to stimulate theca cell proliferation and ovarian androgen production (71) . Furthermore, adipose tissue itself is a site of steroid biosynthesis (72) .
Fetal Programming by Gestational Hyperandrogenism
The programming outcomes related to gestational (maternal or fetal) hyperandrogenism, especially from animal models, have been reviewed extensively (73) (74) (75) and are briefly summarized in the subsequent sections (Fig. 1) . It is worth noting that some effects, such as virilization, are immediate consequences of fetal hyperandrogenism, but others (e.g., metabolic and reproductive dysfunction) are reprogrammed consequences that might not manifest until much later in life.
External genitalia
The phenotypic outcomes of offspring exposed to the gestational hyperandrogenemic environment vary from normal external genitalia in both male and female offspring to ambiguous genitalia in female offspring. Ambiguous genitalia range from clitoral hypertrophy or a phallic structure to labial fusion and an increased anogenital ratio, all of which can be staged using the Prader classification (76) . Fetal CAH is the most frequent cause of genital virilization of female offspring (77) . Luteoma of pregnancy has also been shown to lead to genital virilization of female infants (78) . Gestational hyperandrogenism secondary to PCOS pregnancy has not been shown to lead to genital ambiguity in female offspring (16) .
The degree of virilization of the female genitalia depends on the timing and degree of the androgenic exposure in utero, which has been demonstrated in several animal models. For instance, sheep treated with excess testosterone in utero at 60 to 90 days of gestation (term, 145 days) will have female offspring with normal female external genitalia. However, those treated from 30 to 90 days of gestation (term, 145 days) will be virilized at birth with a noted phallic structure and an increased anogenital ratio (79) .Virilization has also been demonstrated in prenatally androgenized female rat and mouse models (80, 81) , manifesting as an increased anogenital distance and clitoris length.
Fetal growth and birth weight
Intrauterine growth restriction (IUGR) refers to suboptimal in utero fetal growth, with estimated fetal growth less than the 10th percentile due to genetic or in utero environmental perturbation. The prevalence of IUGR varies among developed and underdeveloped countries: 30% to 55% of infants born in South Central Asia, 15% to 25% in Africa, 10% to 20% in Latin America, and 5% to 11% in the United States (82, 83) . IUGR is a risk factor for the development of cardiovascular and metabolic diseases later in life (84) . Some well-known examples of insults leading to IUGR include hypoxia (85), EDCs (86), obesity (87), nicotine (88), excess dexamethasone (89), and nutritional restriction (90) . Relative to the focus of the present review, endogenous circulating maternal androgen levels have been found to be negatively associated with the birth size of the offspring (91) . An increase in circulating maternal testosterone levels from the 25th to the 75th percentile (at 17 weeks of gestation) was found to correspond to a decrease in birth weight of 160 g (91) . The gestational nutritional restriction and cortisol excess linked to IUGR have also been found to be associated with androgen excess (92, 93) . The positive correlation between cortisol and testosterone in these scenarios might be because fetal testosterone is produced partly in the adrenal glands and is under control of adrenocorticotropic hormone, similar to cortisol (93) .
Studies in humans have suggested a link between increased maternal androgen concentrations and the increased proportion of small for gestational age newborns in PCOS pregnancy (94) . The proportion of small for gestational age newborns in PCOS pregnancy was significantly greater relative to newborns of control mothers of Spanish descent (12.8% vs 2.8%) (94) . In contrast to these findings, another study reported large for gestational age infants from women with PCOS (95), suggesting the potential for gene-environment interaction stemming from the genetic and/or ancestral background. In support of a possible link between hyperandrogenism and IUGR, disorders that have been associated with hyperandrogenism during pregnancy, such as preeclampsia, have been associated with IUGR (96) . The absence of IUGR in the offspring of women with CAH (49, 97) might relate to the correction of the hyperandrogenic status because the mothers have received hydrocortisone treatment. Research relating hyperandrogenic disease states such as luteomas and placental aromatase deficiency to IUGR is limited and requires further investigation. Similarly, although evidence exists relating maternal exposure to EDCs with IUGR and low birth weight (98) , to what extent this is a function of maternal androgen excess is unclear. Exposure to BPA, an EDC, has been found to be associated with increased androgen levels in PCOS women (52) .
Animal studies have provided evidence in support of the effect of excess androgen levels on IUGR. In sheep, testosterone treatment of the mother reduced the weight of the newborns of both sexes (99) . Studies of rats have also demonstrated a dose-dependent decrease in birth weight of prenatally testosterone-treated offspring (100). In contrast, prenatal testosterone excess did not culminate in IUGR in rhesus monkeys (101) . These differences might relate to the timing of exposure.
Mechanistically, the programming of IUGR by maternal hyperandrogenism might be mediated via changes press.endocrine.org/journal/endoin placental differentiation or function. In support of this, prenatal testosterone excess has been shown to alter nutrient transfer in rodent models (102, 103) and affect placental differentiation in sheep (104) .
Reproductive dysfunction
Female reproductive disorders manifest as oligomenorrhea, amenorrhea, anovulation, and infertility, to name a few. The prevalence of these disorders can vary depending on various confounding factors. Estimates of the prevalence of infertility ranges from 3.5% to 16.7% in developed nations and 6.9% to 9.3% in less-developed nations (105) . Multiple prenatal insults, including EDC exposure (52), obesity (106), nicotine exposure (107, 108), exposure to excess dexamethasone (109) , and nutritional restriction (110) , which have been found to be associated with excess androgen levels in animal studies, have been linked to reproductive tract disorders in offspring.
Longitudinal follow-up studies of the offspring of hyperandrogenic PCOS mothers are limited, although strong evidence exists for heritability (111) . Studies involving Spanish PCOS women found that the daughters of PCOS women exhibited PCOS-like features, such as elevated testosterone concentrations, increased LH, and increased ovarian volume (112) . An increased ovarian volume might represent an early sign of PCOS development (113) and might be associated with hyperandrogenism. Although fertility is reduced in women with CAH, especially those with the classic salt-wasting type (114), information is limited relative to the reproductive status of the offspring of women with untreated CAH. Earlier studies have indicated that an hyperandrogenic maternal environment in CAH patients can lead to the development of the PCOS phenotype in the female offspring (32) . Studies addressing reproductive function in the offspring of preeclamptic pregnancies are also limited, barring 1 study pointing to a link between IUGR seen in preeclamptic pregnancies and an earlier age at menarche (115) . Human data linking obesity, luteoma, and exposure to EDCs that induce androgen excess in mothers to reproductive outcomes in offspring are also limited.
Studies with well-established precocial animal models have provided proof of concept, indicating that prenatal androgen excess produces reproductive perturbations in the female offspring, culminating in anovulation and infertility later in life (73, 74, 116) . The reproductive defects are manifested as reduced sensitivity to estrogen and progesterone-negative feedback, disrupted estrogenpositive feedback, and increased pituitary sensitivity to gonadotropin-releasing hormone, culminating in hypergonadotropism (LH excess) in rhesus monkeys (117), sheep (116) , and altricial species such as rats (118) .
Anovulation is a common feature of all 3 species; the degree of severity is dependent on the timing of exposure, with late-treated sheep and monkey models showing a lesser degree of severity (74, 119) . Studies of these prenatal androgen excess models have also shown a multifollicular ovarian morphology (73) . Some studies have shown that prenatal testosterone excess also leads to reproductive dysfunctions in the male offspring, manifested as a reduced sperm count and motility and alterations in Sertoli and germ cell number and testicular follicle-stimulating hormone receptor expression (120, 121) .
Metabolic dysfunction
Insulin resistance, diabetes, impaired glucose tolerance, increased visceral adiposity, and hyperinsulinemia are examples of metabolic dysfunction. The prevalence of insulin resistance and hyperinsulinemia is increasing within the United States (122, 123) , and the diagnosis of type 2 diabetes mellitus has almost quadrupled from 1980 to 2010, mirroring the prevalence of obesity in the United States, with a worldwide diabetes prevalence of 8.3% (124) . Multiple prenatal insults, including EDCs (52), obesity (125) , nicotine exposure (107), and nutritional restriction (126) , found to be associated with excess androgen levels, have been linked to metabolic perturbations. Consistent with this, prenatal androgen excess has been shown to be critical in programming the metabolic milieu in the developing fetus in animal models (73, 116) .
Although evidence exists to indicate that the daughters of women with PCOS manifest hyperandrogenism (75) , detailed longitudinal metabolic phenotyping of the offspring of women with PCOS is sparse. Meta-analysis studies have shown that the offspring of PCOS mothers have a greater risk of increased hospitalization for metabolic disorders (127, 128) . The finding of insulin resistance and hyperinsulinemia in offspring born to mothers with PCOS suggests that prenatal androgen excess might be the culprit behind metabolic deficits. The male offspring of mothers with PCOS also have significantly greater low-density lipoprotein cholesterol (129) . Fetal hyperandrogenism in CAH due to 21-hydroxylase deficiency has also been associated with reduced insulin sensitivity (130) .
Considerable evidence has demonstrated an association between maternal obesity and offspring metabolic outcomes. Specifically, obesity, insulin resistance, leptin resistance, hypertension, hepatic steatosis, and nonalcoholic fatty liver disease have all been associated with maternal obesity (126, 131) . However, the extent that these outcomes are related to the androgen excess seen in obese subjects (not all obese women are hyperandrogenic) is unclear. Similarly, although evidence exists supporting the relationship between preeclampsia and type 2 diabetes risk in offspring (132) and elevated maternal EDC levels, such as BPA, with offspring metabolic deficits (133) , to what extent such outcomes are a function of increased maternal androgen levels is unclear. No information is available relative to offspring metabolic programming from luteomas during pregnancy.
Investigations with sheep, monkeys, rodents, and murine models have all provided causal evidence that androgen excess in utero culminates in metabolic perturbations (73, 116, 134, 135) . Female sheep offspring exposed prenatally to excess testosterone show reduced peripheral insulin sensitivity, resulting in hyperinsulinemic states, with the critical period for programming of insulin resistance occurring during gestational days 60 to 90 (136) . These animals also manifest disrupted insulin signaling in insulin target tissues (137, 138) . The adverse programming of insulin sensitivity in prenatal testosterone-treated female offspring is thought to be programmed via androgenic action of testosterone (139, 140) . The offspring of prenatally androgenized rats also exhibit elevated fasting glucose, fasting insulin, and leptin levels from postnatal 5 to 8 weeks and an increase in free fatty acid concentrations at 8 weeks (135) . In addition, homeostatic model assessmentinsulin resistance, a predictor of insulin sensitivity, was found to be substantially greater in the prenatally androgenized group than in controls during puberty (135) . Older prenatal testosterone-treated rhesus monkeys similarly showed adverse insulin sensitivity programming, which manifested as reduced insulin sensitivity, increased adiposity, and glucoregulatory deficits resembling those seen in adult PCOS women (141, 142) .
Interactions among excess androgen levels, lipid metabolism, and cholesterol synthesis have also been implicated in the metabolic programming resulting from gestational testosterone excess in animal models. Prenatal testosterone-treated sheep have an increased number of small adipocytes compared with large adipocytes, which could play a role in the onset of insulin resistance (143, 144) . Recent human studies of obese individuals have suggested that insulin resistance occurs from failure of small adipocytes transitioning to mature adipocytes (145) . Similarly, prenatal testosterone-treated rats (gestational age, 16 to 19 days) were found to have smaller adipocytes and higher triglyceride levels (102) . Gestational testosterone excess in female rhesus monkeys results in accumulation of total abdominal and intra-abdominal fat during the late reproductive age (142) .
Cardiovascular disruptions
Cardiovascular disease is the leading cause of morbidity in both men and women in the United States (146).
It has been estimated that about 610,000 people die of heart disease in the United States every year (146) . Cardiovascular disorders have been linked to multiple prenatal insults, including EDCs (7), obesity (147), nicotine exposure (148) , excess dexamethasone (149) , and nutritional restriction (150) , which have been found to be associated with androgen excess in animal studies. Research investigating an association between PCOS and offspring cardiovascular programming, controlling for obesity, is lacking. One study, which did not control for other risk factors such as maternal diabetes and obesity, reported an association between maternal PCOS and cardiovascular anomalies (127) . Evidence is sparse for reversible abnormal cardiac function in newborns with CAH (151) . In contrast, evidence exists showing an association between preeclampsia and increased blood pressure in offspring (152) . Overall, more research is required to determine whether androgen excess is the mediator of abnormal cardiac programming in these situations.
Animal studies have provided some evidence linking prenatal hyperandrogenism with adverse cardiovascular programming culminating in hypertension in their offspring (153, 154) . The focus of these studies centered around adverse programming of the vasculature, although the mechanisms leading to hypertension are not clear. Evidence relating prenatal androgen excess to programming at the cardiac tissue level is sparse. Preliminary studies in sheep indicated that prenatal testosterone excess leads to enlargement of the left ventricles of the heart in female offspring (155) . Recent follow-up studies have provided histological and molecular evidence for adverse cardiac programming by prenatal testosterone excess (156) . Hypertension and protein kinase C activation in prenatal testosterone-treated rats and their attenuation with androgen receptor antagonist treatment suggests that the hypertension induced by prenatal testosterone excess can be mediated by androgenic activation of the protein kinase C pathway, which controls blood pressure (154) . Considering the presence of androgen and estrogen receptors in cardiac tissues (157) , further studies addressing the direct and indirect effects of prenatal testosterone excess on the cardiovascular system are required.
Behavioral disruptions
It is now well known that sex differences exist in the structure and function of the brain and in behavior (158) . Androgen receptors are present in the cerebral cortex, cerebellum, mediobasal hypothalamus, amygdala, corpus callosum, and cingulate cortex of both sexes (159) . Fetal testosterone levels have been found to be related to specific sexually dimorphic aspects of cognition and doi: 10.1210/en.2016-1801 press.endocrine.org/journal/endobehavior (160) . Evidence points to fetal testosterone and autistic phenotypes (160) . Females with CAH have consistently shown increased male-typical play behavior in childhood, including increased preferences for boys' toys and for boys as playmates and decreased preferences for girls' toys (161) . Additionally, evidence has shown that prenatal exposure to androgen disrupts the circadian clock system in an animal model (162) . It has been hypothesized that developmental programming by androgen excess disrupts the metabolism and reproductive physiology, in part by altering the normal activity of the circadian system (162) . A similar disruption in sleep patterns, including abnormal random eye movement sleep, have been demonstrated in women with PCOS, independent of the presence of obesity and metabolic disorders (163, 164) . Autism spectrum disorder (ASD) is perhaps the most well-studied behavioral programming effect in offspring. According to estimates from the Centers for Disease Control and Prevention Autism and Developmental Disabilities Monitoring Network, about 1 in 68 children has been identified with ASD (165) . It has been suggested that autism might be an extreme manifestation of some male-typical traits, in terms of both cognition and neuroanatomy (160) . Although autism spectrum conditions have a strong neurobiological and genetic component (166) , recent evidence has pointed to prenatal exposure to excess testosterone as 1 culprit in the development of autistic traits (167, 168) . An important positive relationship between fetal testosterone levels and the number of autistic traits using the Childhood Autism Spectrum Test total score, the Child Autism Spectrum Quotient total score, and the 4 subscales of the Child Autism Spectrum Quotient has been reported (160) . That study addressed the relationships between amniotic measurements of fetal testosterone and autistic traits using the Quantitative Checklist for Autism in Toddlers, which allows for the early detection of autism spectrum disorders at 18 to 24 months of age. The fetal testosterone level was the only variable that was significantly related statistically to the Quantitative Checklist for Autism in Toddlers scores, both when the sexes were combined and when the girls and boys were examined separately, suggesting that this is an effect of fetal testosterone levels, rather than sex (169) .
Mechanistically, prenatal androgens might contribute to the development of autism by affecting neuronal density and dendritic morphology, which are thought to be perturbed in autism (158, 170) . Recently, it was demonstrated that D4 sex steroids (testosterone, A4, 17a-hydroxyprogesterone, and progesterone) were elevated in the amniotic fluid of males who were later diagnosed with autism, suggesting a possible disruption of the P450-containing enzymes that are responsible for the conversion of hormones along the D4 sex steroid pathway (168) . Further studies are necessary to address the exact mechanism by which androgens organize the areas of the brain that are involved in the development of autism.
In relating hyperandrogenic conditions to ASDs, 1 study found children born to mothers with PCOS were at 59% greater risk of autism development (171) . Studies have also demonstrated an association between CAH and behavioral programming. One study found that CAH females exhibited more autistic traits, measured using the adult version of the Autism Spectrum Quotient, compared with their unaffected sisters (172) . Meta-analyses of various studies found maternal obesity to be associated with ASD in offspring (173) . Relative to preeclampsia, the findings have been inconsistent, with an older study finding no association between preeclampsia and offspring autism (174) and a recent study demonstrating a strong correlation between preeclampsia and ASD (175) . Developmental exposure to BPA has been shown to lead to a variety of abnormal adult behaviors, including alterations in social, exploratory, and anxiety-like behaviors (176) and behavioral problems in children years later (177) . Experimental studies of androgen excess in animal models have pointed to prenatal testosterone excess leading to behavioral alterations, such as aggression/ dominance (178) and masculine sex behaviors (179); however, focused investigations are required of human hyperandrogenic states to determine whether androgen excess is the mediator of the observed behavioral perturbations.
Mechanisms
The discussed human observational studies and animal experimentation studies have provided evidence in support of the detrimental effects of hyperandrogenic status during development on health outcomes, which span low birth weight, pubertal advancement, and reproductive, metabolic, cardiovascular, and behavioral dysfunction (Fig. 2) . Overall, the expression or severity of the pathologic outcomes appears to be the result of organizational changes induced by the hyperandrogenic status subject to modulation by an activational component that is dictated by the prevailing postnatal environment (75) .
In considering the mechanisms, because excess androgen levels can lead to maternal hyperinsulinemia, as demonstrated in the sheep model of PCOS (180) , steroidal and metabolic pathways are likely to synergize in organizing the final phenotype (140) . Studies involving cotreatment with androgen antagonists and insulin sensitizers have provided support for this premise, with some dysfunctions prevented with androgen antagonist cotreatment and others by insulin sensitizer cotreatment. Furthermore, because androgen excess can influence placental growth and morphology, the effects of hyperandrogenic states can also be mediated via nutritional deficits. Conceivably, metabolic and nutritional milieus might serve as integrative mechanisms via which hyperandrogenemia might lead to adult pathologic features. Epigenetic alterations, such as DNA methylation, histone modification, chromatin packing, and micro-RNA expression, which accumulate over time and alter gene expression are becoming known as key mediators of hyperandrogenic programming. The potential mechanisms of developmental programming by hyperandrogenic status and other insults have been previously reviewed (9) .
Conclusion and Future Direction
The present review has described the various hyperandrogenic states and the phenotype of offspring exposed to prenatal androgen excess. Where feasible, parallels were drawn between human hyperandrogenic states and animal models of prenatal androgen excess. Although a large body of published data exist linking prenatal androgen excess to adult reproductive, metabolic, and behavioral disorders in animal models, data translating these findings to many of the discussed hyperandrogenic states is not available. Prospective human studies addressing the effects of hyperandrogenic pregnancies on offspring health outcomes and placental function would further our understanding of the role that exposure to excess androgen in utero plays in programming the human fetus. To what extent the adverse programming of several body systems is a function of direct androgen action is not clear. Because androgens can be aromatized to estrogen and have been shown to alter insulin-glucose homeostasis in the maternal circulation (134, 180) , further research is required to distinguish direct programming by androgens from that mediated via aromatization to estrogen or altered maternal metabolism. Human association studies of the various hyperandrogenic states, coupled with studies of animal disease models, where causality can be addressed by ablating the various inputs (androgen, estrogen, and insulin), will help determine how androgens program the various health outcomes. If these investigations can unequivocally establish similar pathological outcomes in the offspring after various hyperandrogenic states and their linkage to developmental androgen excess, the maternal androgen level has the potential to be used as a biomarker (Fig. 1) for predicting long-term pathologic outcomes in offspring. press.endocrine.org/journal/endo
